Addressing unmet clinical needs in treatment-resistant breast cancer: expanding the diagnostic-prognostic landscape through next-generation inflammatory signatures.
{"title":"Addressing unmet clinical needs in treatment-resistant breast cancer: expanding the diagnostic-prognostic landscape through next-generation inflammatory signatures.","authors":"Emmanuel Ifeanyi Obeagu","doi":"10.3389/or.2026.1918787","DOIUrl":null,"url":null,"abstract":"<p><p>Treatment-resistant breast cancer remains a major clinical challenge because conventional clinicopathological and molecular biomarkers incompletely capture the dynamic interactions between tumour cells, immunity, inflammation, and the systemic host response. Next-generation inflammatory signatures offer an opportunity to expand the diagnostic-prognostic landscape by integrating cellular, molecular, immune, and thromboinflammatory indicators with established tumour characteristics. This narrative review critically examines emerging evidence for neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, C-reactive protein, cytokines, tumour-associated macrophages, myeloid-derived suppressor cells, neutrophil extracellular traps, coagulation biomarkers, and liquid-biopsy-derived measures in treatment-resistant breast cancer. Particular attention is given to sources of heterogeneity, including population characteristics, tumour subtype, treatment exposure, comorbid inflammation, sampling time, specimen processing, analytical platforms, and inconsistent biomarker thresholds. The review further evaluates the transition from biomarker discovery to clinical decision support, highlighting the need for prospective multicentre validation, standardised analytical procedures, external validation of computational models, and integration with molecular subtyping, circulating tumour DNA, imaging, and immune profiling. Rather than interpreting inflammation as a static prognostic variable, longitudinal inflammatory trajectories may provide earlier signals of biological treatment resistance and complement conventional measures of disease progression. Future research should establish clinically actionable inflammatory combinations and evaluate biomarker-guided anti-inflammatory strategies alongside standard therapies. Ultimately, integrating inflammatory phenotypes with tumour molecular characteristics may facilitate earlier recognition of resistance and more precise, dynamic, and equitable breast cancer management.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1918787"},"PeriodicalIF":4.0000,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719874/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/or.2026.1918787","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Treatment-resistant breast cancer remains a major clinical challenge because conventional clinicopathological and molecular biomarkers incompletely capture the dynamic interactions between tumour cells, immunity, inflammation, and the systemic host response. Next-generation inflammatory signatures offer an opportunity to expand the diagnostic-prognostic landscape by integrating cellular, molecular, immune, and thromboinflammatory indicators with established tumour characteristics. This narrative review critically examines emerging evidence for neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, C-reactive protein, cytokines, tumour-associated macrophages, myeloid-derived suppressor cells, neutrophil extracellular traps, coagulation biomarkers, and liquid-biopsy-derived measures in treatment-resistant breast cancer. Particular attention is given to sources of heterogeneity, including population characteristics, tumour subtype, treatment exposure, comorbid inflammation, sampling time, specimen processing, analytical platforms, and inconsistent biomarker thresholds. The review further evaluates the transition from biomarker discovery to clinical decision support, highlighting the need for prospective multicentre validation, standardised analytical procedures, external validation of computational models, and integration with molecular subtyping, circulating tumour DNA, imaging, and immune profiling. Rather than interpreting inflammation as a static prognostic variable, longitudinal inflammatory trajectories may provide earlier signals of biological treatment resistance and complement conventional measures of disease progression. Future research should establish clinically actionable inflammatory combinations and evaluate biomarker-guided anti-inflammatory strategies alongside standard therapies. Ultimately, integrating inflammatory phenotypes with tumour molecular characteristics may facilitate earlier recognition of resistance and more precise, dynamic, and equitable breast cancer management.
期刊介绍:
Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.